Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.59 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15064815 | 0.87 | BRD4 (0.58) | BRD4CREBBPMAPK1P2RX7 | |
| SCHEMBL807234 | 0.86 | P2RX7 (0.55) | BRD4CREBBPMAPK1P2RX7 | |
| SCHEMBL17877188 | 0.81 | BRD4 (0.65) | BRD4CREBBPMAPK1P2RX7 | |
| SCHEMBL10801839 | 0.81 | MAPK1 (0.76) | BRD4CREBBPMAPK1P2RX7 | |
| SCHEMBL807352 | 0.79 | MAPK1 (0.58) | BRD4CREBBPMAPK1P2RX7 | |
| SCHEMBL10210906 | 0.78 | MAPK1 (0.58) | BRD4CREBBPMAPK1 | |
| SCHEMBL17877197 | 0.78 | BRD4 (0.63) | BRD4CREBBPMAPK1P2RX7 | |
| SCHEMBL17868189 | 0.78 | BRD4 (0.63) | BRD4CREBBPMAPK1P2RX7 | |
| SCHEMBL17868223 | 0.78 | BRD4 (0.63) | BRD4CREBBPMAPK1P2RX7 | |
| SCHEMBL23841127 | 0.78 | BRD4 (0.63) | BRD4CREBBPMAPK1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242981-B2 | Fused pyrazole derivatives as novel ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242981-B2 | Fused pyrazole derivatives as novel ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
| WO-2012036997-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MAPK1, MAPK3, MAP3K1 | BRD4 845/4885CREBBP 183/4885MAPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.